- Home
- SJT vs PROK Comparison
SJT vs PROK Comparison
Compare SJT & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SJT | PROK |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.8M | 331.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SJT | PROK |
|---|---|---|
| Price | $5.66 | $2.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 218.0K | ★ 1.0M |
| Earning Date | 03-30-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $24,557.00 | ★ $744,000.00 |
| Revenue This Year | N/A | $956.51 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.12 | $0.46 |
| 52 Week High | $7.22 | $7.13 |
Technical Indicators
Market Signals| Indicator | SJT | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 46.31 | 46.46 |
| Support Level | $5.45 | $1.87 |
| Resistance Level | $5.75 | $2.12 |
| Average True Range (ATR) | 0.19 | 0.16 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 29.84 | 60.29 |
Price Performance
Historical ComparisonAbout SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.